Condition: Breast Neoplasm Malignant Female · Exercise · Breast Cancer Females · Sponsor: Ankara Etlik City Hospital
This prospective multicenter observational study (NEOBRE-STEP) investigates the impact of daily step counts, measured by Huawei Fit 2 smartwatches, on treatment response in patients with non-metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer undergoing neoadjuvant systemic therapy. Patients will wear smartwatches to continuously record step counts, activity intensity, sleep, and heart rate. Patient-reported outcomes, including sleep quality (Pittsburgh Sleep Quality Index, PSQI) and quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30, EORTC QLQ-C30), will be assessed at baseline and after treatment. The primary outcomes are pathological complete response (pCR) and Miller-Payne score. Secondary outcomes include sleep quality, quality of life, perioperative outcomes, and feasibility of smartwatch monitoring.
This description comes directly from the study's public registry record.
Galip Can Uyar, MD · +905065963812 · g.can_uyar@hotmail.com
Ömür Berna Öksüzoğlu, MD · +905055718475 · bernaoksuzoglu@yahoo.com
Always discuss trial participation with your own doctor first.
| Etlik City Hospital, Medical Oncology Department | Ankara, Yenimahalle, Turkey (Türkiye) | Recruiting |
| Gazi University Medical Oncology Department | Ankara, Çankaya, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07162675